{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:24Z","timestamp":1793212164731,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tofacitinib has emerged as a new potential treatment for acute severe ulcerative colitis [ASUC]. We conducted a systematic review to assess efficacy, safety and integration in ASUC algorithms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Systematic searching was done in MEDLINE, EMBASE, Cochrane Library and Clinicaltrials.gov until August 17, 2022, including all studies reporting original observations on tofacitinib for ASUC, preferably defined according to Truelove and Witts criteria. The primary outcome was colectomy-free survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 1072 publications identified, 21 studies were included of which three were ongoing clinical trials. The remaining comprised a pooled cohort originating from 15 case publications [n\u2005=\u200542], a GETAID cohort study [n\u2005=\u200555], a case-control study [n\u2005=\u200540 cases] and a paediatric cohort [n\u2005=\u200511]. Of these 148 reported cases, tofacitinib was used as second-line treatment after steroid failure in previous infliximab failures or third-line after sequential steroid and infliximab or cyclosporine failure, 69 [47%] were female, median age range was 17\u201334 years and disease duration was 0.7\u201310 years. Overall, 30-day colectomy-free survival was 85% [n\u2005=\u2005123 of 145; n\u2005=\u20053 without colectomy had follow-up &amp;lt;30 days], 90-day 86% [n\u2005=\u2005113 of 132; n\u2005=\u200516 follow-up &amp;lt;90 days] and 180-day 69% [n\u2005=\u200577 of 112; n\u2005=\u200536 follow-up &amp;lt;180 days]. Tofacitinib persistence at follow-up was 68\u201391%, clinical remission 35\u201369% and endoscopic remission 55%. Adverse events occurred in 22 patients, predominantly being infectious complications other than herpes zoster [n\u2005=\u200513], and resulted in tofacitinib discontinuation in seven patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Tofacitinib appears promising for treatment of ASUC with high short-term colectomy-free survival among refractory patients who are otherwise deemed to require colectomy. However, large high-quality studies are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjad036","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T12:47:41Z","timestamp":1677761261000},"page":"1354-1363","source":"Crossref","is-referenced-by-count":69,"title":["Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review"],"prefix":"10.1093","volume":"17","author":[{"given":"Casper","family":"Steenholdt","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Herlev Hospital , Herlev , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"Dige Ovesen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Herlev Hospital , Herlev , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Brynskov","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Herlev Hospital , Herlev , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-7966","authenticated-orcid":false,"given":"Jakob Benedict","family":"Seidelin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Herlev Hospital , Herlev , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"2024090411204483500_CIT0001","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2024090411204483500_CIT0002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ecco-jcc\/jjy154","article-title":"Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort\u2014an Epi-IBD study","volume":"13","author":"Burisch","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024090411204483500_CIT0003","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/flgastro-2020-101710","article-title":"How to manage: Acute severe colitis","volume":"13","author":"Conley","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"2024090411204483500_CIT0004","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"2024090411204483500_CIT0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024090411204483500_CIT0006","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.13491","article-title":"Review article: the practical management of acute severe ulcerative colitis","volume":"43","author":"Seah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2024090411204483500_CIT0007","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.7573\/dic.2021-11-4","article-title":"Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going","volume":"11","author":"Liu","year":"2022","journal-title":"Drugs Context"},{"key":"2024090411204483500_CIT0008","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17474124.2022.2106216","article-title":"Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective","volume":"16","author":"Mishra","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2024090411204483500_CIT0009","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/apt.16482","article-title":"Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis","volume":"54","author":"Honap","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2024090411204483500_CIT0010","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/ibd\/izab087","article-title":"Tofacitinib in acute severe ulcerative colitis: case series and a systematic review","volume":"27","author":"Jena","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024090411204483500_CIT0013","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1093\/ibd\/izab088","article-title":"Tofacitinib in acute severe ulcerative colitis: case series and a systematic review-authors\u2019 reply","volume":"27","author":"Taxonera","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0014","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/2050640620935732","article-title":"Is tofacitinib a game-changing drug for ulcerative colitis","volume":"8","author":"Magro","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"2024090411204483500_CIT0015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024090411204483500_CIT0016","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/ibd\/izy393.050","article-title":"Efficacy of induction therapy with high-intensity to facitinib in 4 patients with acute severe ulcerative colitis","volume":"25","author":"Berinstein","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0017","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/ecco-jcc\/jjaa018","article-title":"Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience","volume":"14","author":"Kotwani","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2024090411204483500_CIT0018","doi-asserted-by":"crossref","first-page":"SS-641","DOI":"10.1016\/S0016-5085(22)61508-7","article-title":"Tofacitinib salvage therapy in pediatric patients hospitalized for ulcerative colitis","volume":"162","author":"Kirsch","year":"2022","journal-title":"Gastroenterology"},{"key":"2024090411204483500_CIT0019","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","article-title":"Tofacitinib salvage therapy for children hospitalized for corticosteroid- and biologic-refractory ulcerative colitis","volume":"75","author":"Constant","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024090411204483500_CIT0020","doi-asserted-by":"crossref","first-page":"S1207","DOI":"10.14309\/01.ajg.0000711176.22796.b5","article-title":"Use of tofacitinib as rescue therapy in a biologic-experienced patient hospitalized with acute severe ulcerative colitis","volume":"115","author":"Bercier","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2024090411204483500_CIT0021","first-page":"130","article-title":"Tofacitinib-induced remission of infliximab-refractory acute severe ulcerative colitis: A case report","volume":"35","author":"Chen","year":"2020","journal-title":"J Gastroenterol Hepatol [Australia]"},{"key":"2024090411204483500_CIT0022","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cgh.2018.11.038","article-title":"Rapid onset of tofacitinib induction therapy for the treatment of ulcerative colitis","volume":"17","author":"Griller","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024090411204483500_CIT0023","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1093\/ibd\/izac015.173","article-title":"High dose tofacitinib as salvage therapy in steroid refractory acute severe ulcerative colitis following non-response to infliximab","volume":"28","author":"Khan","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0024","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/ibd\/izaa357","article-title":"High-dose rescue tofacitinib prevented inpatient colectomy in acute severe ulcerative colitis refractory to anti-TNF","volume":"27","author":"Sedano","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0025","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1093\/ibd\/izab181","article-title":"Success of cyclosporin and tofacitinib combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0026","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/ibd\/izab234","article-title":"Tubercular pleural effusion in a patient of ulcerative colitis treated with tofacitinib","volume":"28","author":"Mishra","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","article-title":"Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis","volume":"16","author":"Gilmore","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024090411204483500_CIT0028","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/ibd\/izaa157","article-title":"Tofacitinib in acute severe ulcerative colitis-a real-world tertiary center experience","volume":"26","author":"Honap","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2024090411204483500_CIT0029","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1007\/s10620-022-07439-2","article-title":"Effectiveness of tofacitinib for hospitalized patients with acute severe ulcerative colitis: case series","volume":"67","author":"Xiao","year":"2022","journal-title":"Dig Dis Sci"},{"key":"2024090411204483500_CIT0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000514781","article-title":"Tofacitinib: an option for acute severe ulcerative colitis","volume":"29","author":"Santos","year":"2022","journal-title":"GE Port J Gastroenterol"},{"key":"2024090411204483500_CIT0031","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjaa198","article-title":"Tofacitinib therapy, the lender of last resort","volume":"15","author":"Rutka","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024090411204483500_CIT0032","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024090411204483500_CIT0033","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort","volume":"54","author":"Uzzan","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2024090411204483500_CIT0034","doi-asserted-by":"crossref","first-page":"SS-988","DOI":"10.1016\/S0016-5085(22)62337-0","article-title":"The real-world effectiveness and safety of corticosterids, calcineurin inhibitor, biologics, and jak inhibitor in hospitalized patients with ulcerative colitis","volume":"162","author":"Naganuma","year":"2022","journal-title":"Gastroenterology"},{"key":"2024090411204483500_CIT0035","doi-asserted-by":"crossref","first-page":"i382","DOI":"10.1093\/ecco-jcc\/jjab232.508","article-title":"Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for acute severe ulcerative colitis","volume":"16","author":"Skinezes","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024090411204483500_CIT0036","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"2024090411204483500_CIT0037","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024090411204483500_CIT0038","doi-asserted-by":"crossref","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2024090411204483500_CIT0039","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjad036\/49633693\/jjad036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/8\/1354\/59016554\/jjad036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/17\/8\/1354\/59016554\/jjad036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:40:29Z","timestamp":1725496829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/8\/1354\/7067135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,3,11]]},"published-print":{"date-parts":[[2023,8,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad036","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,3,11]]}}}